

**Pediatric Clinical Trials Office Research (PCTO)**  
**Neuro-Oncology Clinical Trials Portfolio**

Sponsor ID	Protocol Title	Basic Eligibility	Status
<b>Radiation Only</b>			
COG <a href="#">ACCL2031</a>	A Phase 3 Randomized, Placebo-Controlled Trial Evaluating <b>Memantine</b> (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors	Age 4-17, >15kg, Planned focal, cranial or craniospinal radiation	Active, Enrolling
<b>Medulloblastoma, GCTs and HGGs</b>			
<b>Newly diagnosed</b>			
NEXT Consortium <a href="#">Head Start 4</a>	Newly Diagnosed Children With Medulloblastoma And Other Central Nervous System Embryonal Tumors. Clinical And Molecular Risk-Tailored Intensive & Compressed Induction Chemotherapy Followed By Consolidation With Randomization To Either Single-Cycle Or To Three Tandem Cycles Of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue	Age <10; no prior radiation or chemo; Open only for high-risk; mandatory tissue submission.	Active, Enrolling; Low-risk strata closed
COG <a href="#">ACNS1422</a>	A Phase 2 Study of <b>Reduced Therapy</b> for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients	Age 3-22; rapid central pathology and molecular screen thru PEC; enrolled w/in 36 days after surgery	Active, Enrolling
COG <a href="#">ACNS1723</a>	A Phase 2 Study of <b>Dabrafenib with Trametinib</b> after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG)	Age 3-21; rapid central pathology and molecular screen thru PEC; enrolled w/in 31 days of surgery	Active, Enrolling
ACTION <a href="#">MCC18752</a>	ACTION Trial: <b>Adoptive Cellular Therapy</b> Following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas	Age 3-21; residual post-surgical dz burden <3cm	Slots, case by case
COG <a href="#">ACNS1821</a>	A Phase 1/2 Trial of <b>Selinexor (KPT-330) and Radiation Therapy</b> in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)	Age 1-21; DMG included w/o BRAF <sup>V600</sup> or IDH1, w/o biopsy patients to be start treatment within 31 days of dx; no metastatic disease	Temp. closed to accrual

<a href="#">PNOC022</a>	A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at <b>Initial Diagnosis, Post-Radiation Therapy and at Time of Progression</b>	Age 2-39, H3K27M, prior use of TMZ allowed, criteria vary per cohort. Excl-H3 wildtype Gr2 diffuse astrocytoma	Active, Cohort 2 enrolling. Cohort 1&3 on HOLD
<a href="#">ACNS2021</a>	A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized <b>Non-Germinomatous Central Nervous System Germ Cell Tumor</b>	Age 3-30, therapy must begin within 31 calendar days of definitive surgery or dx. Required CSF markers	Active, Enrolling
<b>Relapsed/Refractory/Recurrent</b>			
<a href="#">PEPN2111</a>	A Phase 1/2 Trial of <b>CBL0137</b> in Patients With Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	Age 1-21 Part A: r/r CNS tumors Part B1: progressive DIPG	Enrollment on HOLD
<a href="#">PEPN2121</a>	<b>Tiragolumab</b> and <b>Atezolizumab</b> for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	Age ≥1, r/r OR newly dx'd, ATRT, chordoma, or SMARC deficient tumors; must have measurable dz	Active, Enrolling
<a href="#">APEC1621SC</a> PedsMatch	NCI-COG Pediatric Match (Molecular Analysis For Therapy Choice) Screening Protocol (Sub-protocol drugs: larotrectinib, erdafitinib, ivosidenib, LY3023414)	Age 1- ≤ 21; r/r CNS tumors. Must have tissue available OR sequencing done	Active, Enrolling
<a href="#">PNOC019</a>	A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with <b>Recurrent or Progressive High-Grade Glioma (HGG)</b>	Age 6 months to 22 years; undergo resection, Performance score ≥ 50, Ex- leptomenigeal dz	Active, IND supply issues
<a href="#">UAB18113</a>	Phase 1 Trial of Engineered HSV <b>G207</b> in Children with Recurrent or Refractory Cerebellar Brain Tumors	≥ 36 months to < 19 years	Active, Enrolling
<b>NF and LGGs</b>			
<b>Newly diagnosed, Untreated progressive</b>			
COG <a href="#">ACNS1831</a>	A Phase 3 Randomized Study of <b>Selumetinib versus Carboplatin/Vincristine</b> in Newly Diagnosed or Previously <b>Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma</b>	Age 2-21; measurable dz ≥ 1cm <sub>2</sub> ; must be able to swallow capsule; screen thru PEC; IOP WNL	Active, Enrolling

COG <a href="#">ACNS1833</a>	A Phase 3 Randomized Non-Inferiority Study of <b>Carboplatin and Vincristine versus Selumetinib</b> in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) <b>not associated with BRAFV600E Mutations or Systemic NF1</b>	Age 2-21; rapid review thru PEC; 2D measurable dz $\geq 1\text{cm}^2$ ; must be able to swallow capsule; IOP WNL	Active, Enrolling
Neurofibromatosis Consortium <a href="#">NF110</a>	Open-label, Phase 2 Clinical Trial of <b>Crizotinib</b> for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas	Age $\geq 6$ ; measurable dz, radiologic evidence of progression	Enrollment on HOLD
<b>Relapsed/recurrent, Previously treated progressive</b>			
Neurofibromatosis Consortium <a href="#">NF111</a>	A Phase II Trial of <b>Poly-ICLC</b> for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1	Age $<22$ ; measurable dz; Excluded: prior radiation, malignant glioma; high dose steroids	Active, Enrolling
COG <a href="#">ACNS1931</a>	A Phase 3 Study of <b>Selumetinib or Selumetinib in Combination With Vinblastine</b> for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations	Age 2-25; BSA $\geq 0.5$ ; Rapid central and molecular screening thru PEC; measurable dz	Active, Enrolling
<a href="#">PNOC021</a>	A Phase I Trial Evaluating the Combination of <b>Trametinib and Everolimus</b> in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas	Age 1-25; genomic testing required; Excluded: surgery alone, K27M mutation	Enrollment on HOLD